211 related articles for article (PubMed ID: 37167646)
1. Human papillomavirus genotypic characteristics of 60,685 subjects under age-expansion vaccination of the nine-valent human papillomavirus vaccine: A cross-sectional study.
Liu Y; Li Z; Yuan L; Liu F; Wu K; Xiao X; Zhu C
J Infect Public Health; 2023 Jul; 16(7):989-995. PubMed ID: 37167646
[TBL] [Abstract][Full Text] [Related]
2. HPV genotypic spectrum in Jilin province, China, where non-vaccine-covered HPV53 and 51 are prevalent, exhibits a bimodal age-specific pattern.
Hao S; Wang C; Liu S; He J; Jiang Y
PLoS One; 2020; 15(3):e0230640. PubMed ID: 32208459
[TBL] [Abstract][Full Text] [Related]
3. A retrospective analysis of human papillomavirus (HPV) prevalence and genotype distribution among 25,238 women in Shanghai, China revealed the limitations of current HPV-based screening and HPV vaccine.
Ruan Y; Li H; Liu M; Cao G; Xu X; Han L; Li F
Cancer Epidemiol; 2023 Jun; 84():102372. PubMed ID: 37119603
[TBL] [Abstract][Full Text] [Related]
4. HPV prevalence and genotype distribution among women in Shandong Province, China: Analysis of 94,489 HPV genotyping results from Shandong's largest independent pathology laboratory.
Jiang L; Tian X; Peng D; Zhang L; Xie F; Bi C; Wang R; Wang J; Qi D
PLoS One; 2019; 14(1):e0210311. PubMed ID: 30653566
[TBL] [Abstract][Full Text] [Related]
5. Prevalence of vaccine and non-vaccine human papillomavirus types among women in Accra and Kumasi, Ghana: a cross-sectional study.
Debrah O; Agyemang-Yeboah F; Donkoh ET; Asmah RH
BMC Womens Health; 2021 Oct; 21(1):372. PubMed ID: 34702246
[TBL] [Abstract][Full Text] [Related]
6. Nationwide prevalence of human papillomavirus infection and viral genotype distribution in 37 cities in China.
Wang R; Guo XL; Wisman GB; Schuuring E; Wang WF; Zeng ZY; Zhu H; Wu SW
BMC Infect Dis; 2015 Jul; 15():257. PubMed ID: 26142044
[TBL] [Abstract][Full Text] [Related]
7. Public health impact of 2-, 4-, and 9-valent HPV vaccination in females on cervical and noncervical diseases in men and women under different coverage scenarios in China: A simulation study.
Diakite I; Kyle J; Situ S; Bai P; Zhang X; Wang W; Daniels V
Hum Vaccin Immunother; 2023 Aug; 19(2):2258569. PubMed ID: 37787054
[TBL] [Abstract][Full Text] [Related]
8. Assessing the epidemiological impact on cervical cancer of switching from 4-valent to 9-valent HPV vaccine within a gender-neutral vaccination programme in Switzerland.
Kind AB; Pavelyev A; Kothari S; El Mouaddin N; Schmidt A; Morais E; Guggisberg P; Lienert F
BMC Public Health; 2020 May; 20(1):671. PubMed ID: 32398057
[TBL] [Abstract][Full Text] [Related]
9. Distribution of human papillomavirus genotypes in western China and their association with cervical cancer and precancerous lesions.
Li J; Gao JJ; Li N; Wang YW
Arch Virol; 2021 Mar; 166(3):853-862. PubMed ID: 33486629
[TBL] [Abstract][Full Text] [Related]
10. Human papillomavirus prevalence and genotype distribution among young women and men in Maputo city, Mozambique.
Edna Omar V; Orvalho A; Nália I; Kaliff M; Lillsunde-Larsson G; Ramqvist T; Nilsson C; Falk K; Nafissa O; Ilesh Vindorai J; Andersson S
BMJ Open; 2017 Jul; 7(7):e015653. PubMed ID: 28716790
[TBL] [Abstract][Full Text] [Related]
11. Prevalence of high-risk HPV genotypes, categorised by their quadrivalent and nine-valent HPV vaccination coverage, and the genotype association with high-grade lesions.
Paz-Zulueta M; Álvarez-Paredes L; Rodríguez Díaz JC; Parás-Bravo P; Andrada Becerra ME; Rodríguez Ingelmo JM; Ruiz García MM; Portilla J; Santibañez M
BMC Cancer; 2018 Jan; 18(1):112. PubMed ID: 29382323
[TBL] [Abstract][Full Text] [Related]
12. Human papillomavirus genotype distribution among women with and without cervical cancer: Implication for vaccination and screening in Ghana.
Nartey Y; Amo-Antwi K; Hill PC; Dassah ET; Asmah RH; Nyarko KM; Agambire R; Konney TO; Yarney J; Damale N; Cox B
PLoS One; 2023; 18(1):e0280437. PubMed ID: 36656844
[TBL] [Abstract][Full Text] [Related]
13. Trends in prevalence in human papillomavirus types and their association with cervical dysplasia: an analysis on 15 138 women over 20 years.
Bogani G; Chiappa V; Pinelli C; Lopez S; Signorelli M; Taverna F; Lombardo C; Ditto A; Raspagliesi F
Eur J Cancer Prev; 2020 Sep; 29(5):452-457. PubMed ID: 32740171
[TBL] [Abstract][Full Text] [Related]
14. Distribution of Vaccine-Type Human Papillomavirus Does Not Differ by Race or Ethnicity Among Unvaccinated Young Women.
Whittemore D; Ding L; Widdice LE; Brown DA; Bernstein DI; Franco EL; Kahn JA
J Womens Health (Larchmt); 2016 Nov; 25(11):1153-1158. PubMed ID: 27754751
[TBL] [Abstract][Full Text] [Related]
15. Human papillomavirus vaccine effect against human papillomavirus infection in Rwanda: evidence from repeated cross-sectional cervical-cell-based surveys.
Sayinzoga F; Tenet V; Heideman DAM; Sibomana H; Umulisa MC; Franceschi S; Hakizimana JD; Clifford GM; Baussano I
Lancet Glob Health; 2023 Jul; 11(7):e1096-e1104. PubMed ID: 37207683
[TBL] [Abstract][Full Text] [Related]
16. Human papillomavirus prevalence and type-distribution, cervical cancer screening practices and current status of vaccination implementation in Central and Eastern Europe.
Poljak M; Seme K; Maver PJ; Kocjan BJ; Cuschieri KS; Rogovskaya SI; Arbyn M; Syrjänen S
Vaccine; 2013 Dec; 31 Suppl 7():H59-70. PubMed ID: 24332298
[TBL] [Abstract][Full Text] [Related]
17. Pre-vaccination prevalence and genotype distribution of human papillomavirus infection among women from urban Tunis: a cross-sectional study.
Guettiti H; Ennaifer E; Attia L; Chelly D; Alaya NB; Aissa RB; Laassili T; Boubaker S
Asian Pac J Cancer Prev; 2014; 15(21):9361-5. PubMed ID: 25422225
[TBL] [Abstract][Full Text] [Related]
18. Immunogenicity, efficacy, and safety of human papillomavirus vaccine: Data from China.
Li M; Zhao C; Zhao Y; Li J; Wei L
Front Immunol; 2023; 14():1112750. PubMed ID: 36993948
[TBL] [Abstract][Full Text] [Related]
19. Prevalence and human papillomavirus (HPV) genotype distribution in Suzhou, China.
Wang T; Luan L; Deng J; Liu N; Wu Q; Gong T; Zhu J; Zhang Z; Zhang J
Hum Vaccin Immunother; 2023 Aug; 19(2):2241309. PubMed ID: 37519009
[TBL] [Abstract][Full Text] [Related]
20. The clinical effectiveness and cost-effectiveness of primary human papillomavirus cervical screening in England: extended follow-up of the ARTISTIC randomised trial cohort through three screening rounds.
C Kitchener H; Canfell K; Gilham C; Sargent A; Roberts C; Desai M; Peto J
Health Technol Assess; 2014 Apr; 18(23):1-196. PubMed ID: 24762804
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
